These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31019903)

  • 1. Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Terashima T; Yamashita T; Toyama T; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
    Liver Cancer; 2019 Mar; 8(2):130-139. PubMed ID: 31019903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.
    Lee DW; Jang MJ; Lee KH; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH; Kim TY; Han SW; Oh DY; Im SA; Kim TY
    Br J Cancer; 2016 Nov; 115(10):1201-1205. PubMed ID: 27736843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?
    Celsa C; Cabibbo G; Enea M; Battaglia S; Rizzo GEM; Busacca A; Giuffrida P; Stornello C; Brancatelli G; Cannella R; Gruttadauria S; Cammà C
    Liver Int; 2021 May; 41(5):1105-1116. PubMed ID: 33587814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib.
    Terashima T; Yamashita T; Takata N; Nakagawa H; Toyama T; Arai K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
    Hepatol Res; 2016 Jun; 46(7):650-6. PubMed ID: 26441378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
    Petrelli F; Barni S
    Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
    Li L; Pan Z
    Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
    Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Tremblay G
    Breast Cancer (Dove Med Press); 2018; 10():69-78. PubMed ID: 29765247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Yang Y; Wang J; Wang W; Zhang T; Zhao J; Wang Y; Li Y; Wang L; Bi N
    Front Oncol; 2022; 12():810580. PubMed ID: 35155246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma.
    Jin Y; Ren H; Yue Q; Wu W; Liu C; Guo Y; Zhao P
    BMC Cancer; 2024 Feb; 24(1):258. PubMed ID: 38395854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.
    Cabibbo G; Celsa C; Enea M; Battaglia S; Rizzo GEM; Busacca A; Matranga D; Attanasio M; Reig M; Craxì A; Cammà C
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis.
    Sjoquist KM; Lord SJ; Friedlander ML; John Simes R; Marschner IC; Lee CK
    Ther Adv Med Oncol; 2018; 10():1758835918788500. PubMed ID: 30093922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization.
    Wang H; Li B; Wang Y; Zhang J; Wu Y; Fan W; Li J
    J Cancer Res Ther; 2020; 16(2):301-308. PubMed ID: 32474517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.
    Llovet JM; Montal R; Villanueva A
    J Hepatol; 2019 Jun; 70(6):1262-1277. PubMed ID: 30943423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling Overall Survival in Patients With Pancreatic Cancer From a Pooled Analysis of Phase II Trials.
    Kabir ER; Azam F; Khan TTS; Yasmin H; Chowdhury NM; Ahmed SM; Sagar BH; Tahrim NA
    Cancer Med; 2024 Oct; 13(19):e70289. PubMed ID: 39387320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.
    Shitara K; Ikeda J; Yokota T; Takahari D; Ura T; Muro K; Matsuo K
    Invest New Drugs; 2012 Jun; 30(3):1224-31. PubMed ID: 21350803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer.
    Garside J; Shen Q; Westermayer B; van de Ven M; Kroep S; Chirikov V; Juhasz-Böss I
    Clin Ther; 2023 Oct; 45(10):983-990. PubMed ID: 37689551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
    BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.
    Delea TE; Khuu A; Heng DY; Haas T; Soulières D
    Br J Cancer; 2012 Sep; 107(7):1059-68. PubMed ID: 22935581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.
    Reig M; Rimola J; Torres F; Darnell A; Rodriguez-Lope C; Forner A; Llarch N; Ríos J; Ayuso C; Bruix J
    Hepatology; 2013 Dec; 58(6):2023-31. PubMed ID: 23787822
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.